Skip to main content
Clinical Trials/NCT06616454
NCT06616454
Recruiting
Not Applicable

The Effect of Time-Restricted Feeding on Body Composition and Some Metabolic Parameters in Obese Adolescents

Sümeyra Başar1 site in 1 country60 target enrollmentOctober 14, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Adolescent Obesity
Sponsor
Sümeyra Başar
Enrollment
60
Locations
1
Primary Endpoint
Changes in body weight
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Obesity is now recognized as a serious public health problem. It is known that obesity seen in adolescence is largely carried over to adulthood. Therefore, its treatment is important both in terms of protecting current health and preventing diseases in adulthood. Reducing energy intake plays an important role in the treatment of obesity. However, long-term adherence and effectiveness to energy restriction appear to be limited. Therefore, the need for interventions that are "effective in body weight loss" and "accessible, simple and lifestyle modification to increase dietary compliance" is clear. Time-restricted feeding is a specialized intermittent fasting protocol that includes consistent fasting and eating periods over a 24-hour cycle by supporting circadian rhythms. Especially in the adult population, positive effects of time-restricted feeding such as weight loss and blood glucose regulation are observed. However, there are limited data on this subject for adolescents. Today, the Mediterranean diet, which is one of the nutrition models that supports health, is a beneficial nutritional model that reduces body weight and obesity-related comorbidities by limiting total energy intake. However, no study has been found in the literature in which the effectiveness of time-restricted nutrition, which is a new and promising approach, and the Mediterranean diet, which is a sustainable diet model, are evaluated together. Therefore, in this study, it was aimed to evaluate the effects of planned time-restricted nutrition compatible with circadian rhythm and energy-restricted feeding planned according to the Mediterranean diet model on body composition and various metabolic parameters in obese adolescents. 60 obese adolescents aged 12-18 years will be included in this randomized controlled and parallel design study. Participants will be randomized to one of two treatment groups for a 12-week intervention. The time-restricted feeding group will form the intervention group of the study, and the energy-restricted feeding group will form the control group. Anthropometric measurements of the participants at the beginning and end of the study will be taken, and various biochemical parameters will be evaluated with the body composition and blood samples to be taken. As a result of the study, it is expected to determine the effectiveness of time-restricted feeding compared to energy-restricted feeding in terms of dietary compliance, body composition and biochemical changes.

Registry
clinicaltrials.gov
Start Date
October 14, 2024
End Date
August 15, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sümeyra Başar
Responsible Party
Sponsor Investigator
Principal Investigator

Sümeyra Başar

project manager

TC Erciyes University

Eligibility Criteria

Inclusion Criteria

  • Adolescents aged 12-18 with puberty stage:5
  • Obese adolescents with a metabolic disorder (such as fatty liver, insulin resistance, prediabetes, dyslipidemia) (BMI≥95th percentile for age)
  • Those who have a stable body weight for 3 months before the start of the study (current weight gain or loss \<4 kg)
  • Those who own and can use a Smartphone with Apple iOS or Android operating system
  • Those who speak, read and understand Turkish

Exclusion Criteria

  • Those with any endocrine disorder, metabolic, chronic or major psychiatric disease other than obesity, insulin resistance, dyslipidemia, prediabetes, fatty liver
  • Polycystic ovary syndrome (PCOS)
  • Those with physical or mental disabilities
  • Those with allergies, intolerances or eating disorders
  • Those who smoke and drink alcohol
  • Use of drugs that may affect study results, circadian rhythms or metabolism (such as antidiabetics, steroids, beta blockers, adrenergic stimulating agents, laxatives, etc.)

Outcomes

Primary Outcomes

Changes in body weight

Time Frame: Baseline, Week 4, Week 8 and Week 12

Changes in body weight will be examined as a result of the implemented nutrition plan.

Changes in body fat percentage

Time Frame: Baseline, Week 4, Week 8 and Week 12

Changes in body fat percentage as a result of the implemented nutrition plan will be examined. The fat percentage will be assessed based on measurements taken with bioimpedance analysis devices.

Changes in body mass index

Time Frame: Baseline, Week 4, Week 8 and Week 12

Changes in body mass index as a result of the implemented nutrition plan will be examined. Body mass index (BMI) will be calculated based on changes in height (cm) and weight (kg) values, using the formula kg/m².

Biochemical changes

Time Frame: Baseline and Week 12

As a result of the implemented nutrition plan, changes in fasting glucose (mg/dL), total cholesterol (mg/dL), LDL cholesterol (LDL-C; mg/dL), HDL cholesterol (HDL-C; mg/dL), and triglycerides (mg/dL) levels will be evaluated.

Changes in glycated hemoglobin levels

Time Frame: Baseline and Week 12

As a result of the implemented nutrition plan, changes in glycated hemoglobin (HbA1c) levels will be evaluated.

Changes in insulin levels

Time Frame: Baseline and Week 12

As a result of the implemented nutrition plan, changes in insulin levels (measured in µIU/mL) will be evaluated.

Changes in hormone levels

Time Frame: Baseline and Week 12

At the conclusion of the implemented nutrition plan, changes in the levels of leptin, ghrelin, adiponectin, irisin, and nesfatin hormones (ng/mL) will be evaluated.

Changes in inflammatory markers

Time Frame: Baseline and Week 12

At the conclusion of the implemented nutrition plan, changes in various inflammation markers, including interleukin (IL)-17, IL-10, IL-6, IL-1β, and TNF-α (ng/mL), will be evaluated.

Study Sites (1)

Loading locations...

Similar Trials